Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZA
Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics, and Radiopharmaceutical Chemistry and Applications.
Patterns of intra- and intertumor phenotypic heterogeneity in lethal prostate cancer
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial
Abstract 3402: Number of variants of unknown significance (VUS) by next generation sequencing (NGS) and response to systemic therapies in advanced urothelial carcinoma (aUC)
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates
Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer
1804P APEX-01: First-in-human phase I/II study of ARX517 an anti- prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
Nucleosome Patterns in Circulating Tumor DNA Reveal Transcriptional Regulation of Advanced Prostate Cancer Phenotypes
Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
<i>CDK12</i>-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade
Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations
A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
Microsatellite instability in prostate cancer by PCR or next-generation sequencing
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
MSH2 Loss in Primary Prostate Cancer
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
Small cell carcinoma of the prostate